Status:
COMPLETED
Stents, Drug Eluting Stents, and CABG- Financial and Clinical Impact.
Lead Sponsor:
Shaare Zedek Medical Center
Collaborating Sponsors:
Hebrew University of Jerusalem
Conditions:
Coronary Arteriosclerosis
Angina Unstable
Eligibility:
All Genders
Brief Summary
Options for coronary revascularization include stent implantation and coronary bypass surgery. Both modalities have their unique advantages and disadvantages in terms of clinical outcomes as well as f...
Detailed Description
Cardio-vascular disease is the second leading cause of death in the western world. Two modes of treatment are currently used: Coronary Artery Bypass Graft (CABG) Percutaneous Interventions (PCIs) i.e...
Eligibility Criteria
Inclusion
- Patients which are insured in the relevant HMO's and suffer from a multi-vessel coronary disease with occlusion of at least 70% of at least two of the main coronary vessels.
Exclusion
- Non multi- vessel Disease
- Any additional cardiac disease
- Valvular
- Low EF (\<30%)
- Liver disease - according to liver enzymes
- Other cardiac treatment (past or immediate future)
- Active MI (24hrs before revascularization)
- Previous revascularization before beginning of follow up.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2007
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT00394680
Start Date
November 1 2006
End Date
May 1 2007
Last Update
May 27 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.